Prognostic value of JAK2V617F mutation in pseudotumor cerebri associated with cerebral venous sinus thrombosis

被引:4
|
作者
Zloto, Ofira [1 ,2 ]
Lubetsky, Aharon [3 ]
Mizrachi, Iris Ben-Bassat [2 ]
Kesler, Anat [1 ]
Quiros, Peter A. [4 ]
Huna-Baron, Ruth [1 ,2 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[2] Sheba Med Ctr, Neuroophthalmol Unit, Tel Hashomer, Israel
[3] Sheba Med Ctr, Thrombosis & Hemostasis Unit, Tel Hashomer, Israel
[4] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA
来源
ACTA NEUROLOGICA SCANDINAVICA | 2019年 / 139卷 / 02期
关键词
cerebral venous sinus thrombosis; JAK2V617F mutation; pseudotumor cerebri; JAK2 V617F MUTATION; POLYCYTHEMIA-VERA; THROMBOEMBOLISM; RISK;
D O I
10.1111/ane.13032
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives To examine the clinical characteristics and prognosis of cerebral venous sinus thrombosis (CVST) that presented as pseudotumor cerebri (PTC) patients with JAK2V617F mutation. Methods Medical records of all consecutive patients that presented with PTC and a JAK2V617F mutation who were treated were retrospectively reviewed. Data regarding demographics and ocular presenting symptoms and signs, neurological signs, hematological factors treatment, and prognosis were collected. Results The most common presenting symptoms were headache (5 patients, 83.3%) and visual obscurations (5 patients, 83.3%). CVST of the sagittal sinus and sigmoid sinus were the most common site of thrombus. Platelet count and hemoglobin count were higher than normal during follow-up. There was significant change in the disk edema degree as well as decline in retinal nerve fiber layer (RNFL) thickness (P < 0.001, P < 0.001, Matched pairs). There was no significant change in visual acuity (VA) or mean deviation (MD) during follow-up (P = 0.95, 0.64, respectively, Matched pairs). Conclusions Pseudotumor cerebri resulting from CSVT in our patients with JAK2V617F mutation was frequent in young patients and needed medical and surgical treatment, without improvement in visual functions and in third caused poor visual outcome. Therefore, we believe that a screening test for JAK2V617F mutation should be considered for patients with CVST without known risk factor presenting with PTC, especially when sagittal sinus or sigmoid sinus involvement or thrombocytosis or high hemoglobin are found upon presentation. This might lead to more aggressive management which may improve the visual prognosis of those young patients.
引用
收藏
页码:166 / 171
页数:6
相关论文
共 50 条
  • [31] JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia
    Aswad, Mohamed Hussam
    Kissova, Jarmila
    Ovesna, Petra
    Rihova, Lucie
    Penka, Miroslav
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2023, 84 (04) : 359 - 368
  • [32] Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation
    Janjetovic, Snjezana
    Beckmann, Lennart
    Holstein, Katharina
    Rolling, Christina
    Thiele, Benjamin
    Schafhausen, Philippe
    Schoen, Gerhard
    Bokemeyer, Carsten
    Langer, Florian
    Voigtlaender, Minna
    THROMBOSIS RESEARCH, 2021, 198 : 55 - 61
  • [33] Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?
    Uyanik, Mehmet Sevki
    Baysal, Mehmet
    Pamuk, Gulsum Emel
    Maden, Muhammet
    Akker, Mustafa
    Umit, Elif Gulsum
    Demir, Muzaffer
    Aydogdu, Erkan
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2016, 32 (03) : 262 - 267
  • [34] Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms
    Singh, Kanwaljeet
    Sazawal, Sudha
    Chhikara, Sunita
    Mahapatra, Manoranjan
    Saxena, Renu
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2018, 61 (03) : 371 - 374
  • [35] Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms
    Mullally, A.
    PATHOLOGE, 2016, 37 : 175 - 179
  • [36] JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia
    Rossi, Davide
    Cresta, Stefania
    Destro, Tamara
    Vendramin, Chiara
    Bocchetta, Simone
    De Paoli, Lorenzo
    Cerri, Michaela
    Lunghi, Monia
    Gaidano, Gianluca
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (06) : 813 - 814
  • [37] JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia
    Randi, Maria Luigia
    Ruzzon, Elisabetta
    Tezza, Fabiana
    Scapin, Margherita
    Duner, Elena
    Scandellari, Raffaella
    Fabris, Fabrizio
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2011, 23 (01) : 17 - 21
  • [38] Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis
    De Moner, Blanca
    Martinez-Sanchez, Julia
    Garrote, Marta
    Ramos, Alex
    Ventosa-Capell, Helena
    Moreno-Castano, Ana
    Nomdedeu, Meritxell
    Ojeda, Asuncion
    Escolar, Gines
    Garcia-Pagan, Joan Carles
    Arellano-Rodrigo, Eduardo
    Carreras, Enric
    Alvarez-Larran, Alberto
    Diaz-Ricart, Maribel
    THROMBOSIS AND HAEMOSTASIS, 2025,
  • [39] Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders
    De, Tanima
    Prabhakar, Puttachandra
    Nagaraja, Dindagur
    Christopher, Rita
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 323 (1-2) : 178 - 182
  • [40] QUANTITATIVE EVALUATION OF JAK2V617F MUTATION AND BCR-ABL P210 TRANSLOCATION IN PATIENTS WITH SIMULTANEOUS JAK2V617F MUTATION AND BCR-ABL TRANSLOCATION
    Abdullaev, A. O.
    Treglazova, S. A.
    Skorobogatova, A., V
    Makarik, T., V
    Stepanova, E. A.
    Shukhov, O. A.
    Turkina, A. G.
    Melikyan, A. L.
    Kovrigina, A. M.
    Sudarikov, A. B.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2015, 60 (01): : 29 - 32